Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users
过量教育和向海洛因使用者开纳洛酮处方的风险和益处
基本信息
- 批准号:8694865
- 负责人:
- 金额:$ 54.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-15 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAddressAdverse eventAffectAreaBehaviorBenefits and RisksCessation of lifeDataData AnalysesDrug CombinationsDrug Metabolic DetoxicationDrug usageEducationEffectivenessEffectiveness of InterventionsEmergency SituationFrequenciesFriendsFundingGrantHarm ReductionHealthHealth PersonnelHeroinHeroin UsersHuman ResourcesIllicit DrugsImprisonmentIncentivesIndividualInstructionInterventionInvestigationKnowledgeLocationMeasuresMedicalMental HealthMethodsModificationNaloxoneNarcotic AntagonistsNeedle-Exchange ProgramsNeighborhoodsNew York CityOpioidOutcomeOutcome MeasureOverdoseParticipantPatient Self-ReportPatternPersonsPharmaceutical PreparationsPoisoningPopulationPremature MortalityPrevalencePreventionPrevention programProspective StudiesPublic HealthRandomizedRecording of previous eventsRecruitment ActivityRelative (related person)ReportingResearchResuscitationRetrospective StudiesReview LiteratureRisk-Benefit AssessmentSafetySedation procedureServicesSiteSodium ChlorideSolutionsSpousesSymptomsTechniquesTimeTrainingTraining ProgramsTraining and EducationVentilatory DepressionWaterdesignexperiencefollow-upheroin overdosehigh riskimprovedmortalitynovelnovel strategiesopioid abuseoverdose deathoverdose preventionprescription opioidprogramsprospectivepsychosocialpublic health relevanceresponsesubstance abusertreatment as usual
项目摘要
DESCRIPTION (provided by applicant): Heroin overdose is the leading cause of premature mortality among heroin users (Smyth et al., 2007), and is the second most common drug responsible for poisoning deaths in New York City. Although deaths due to unintentional drug overdose decreased overall by 24% in NYC between 2005 and 2009, prescription opioid deaths increased by 20% during this same time period (Epi Data Brief, New York City Department of Health and Mental Hygiene (NYC DOHMH), 2011). A new harm reduction approach attempts to decrease opioid overdose by educating users in recognizing its symptoms and in using naloxone to reverse opioid-induced respiratory depression. In the proposed studies, we will attempt to obtain data on the impact that these programs may have on the health and outcomes of a population of opioid users at high risk for witnessing and experiencing an opioid overdose. We have preliminary evidence supporting the need for modifications of existing training programs to improve accurate identification of opioid overdose. Furthermore, a review of the literature has revealed that more extensive research, including proactive, long-term follow-up, is needed to better identify all of the benefits and risks associated with this approach. Specifically our investigation will recruit ongoing and recently detoxified opioid abusers from several sites throughout the NYC area. All participants will receive standard opioid overdose education training and naloxone to carry should they witness another person experiencing an overdose, or overdose themselves. One-third of the participants will be randomized to receive additional in-depth psychosocial education focusing on recognition and prevention of opioid overdose, and appropriate use of naloxone. Another one-third of the participants will receive the extensive training and be required to engage a spouse, partner, relative, or friend in this supplementary intervention. We expect that these psychosocial interventions (extensive training and training of a significant other) will improve overdose outcome measures. We also expect that the occurrence of naloxone-related adverse events will be minimal, and that access to naloxone will not significantly alter drug use patterns. The results of this study should provide one of the firs prospective and systematic assessments of the risks and benefits of this novel practice in the U.S., and educate the field on how we may improve upon current practices. In addition to conducting a prospective study, we also propose to conduct a retrospective analysis of the overall impact of overdose education and training in the use of naloxone by examining data collected by the NYC DOHMH. Specifically, both fatal and non-fatal opioid overdose rates will be compared in neighborhoods with facilities that offer overdose prevention training and naloxone to those that do not. We anticipate that the prevalence of fatal opioid overdose will be significantly lower in neighborhoods where opioid overdose prevention training and naloxone are offered.
描述(由申请人提供):海洛因过量服用是海洛因使用者过早死亡的主要原因(Smyth 等人,2007 年),也是纽约市第二大中毒死亡的最常见药物。尽管 2005 年至 2009 年间,纽约市因意外药物过量导致的死亡总体下降了 24%,但同期处方阿片类药物死亡人数却增加了 20%(Epi 数据简报,纽约市健康和心理卫生局 (NYC DOHMH), 2011)。一种新的减少危害方法试图通过教育使用者认识其症状并使用纳洛酮逆转阿片类药物引起的呼吸抑制来减少阿片类药物过量服用。在拟议的研究中,我们将尝试获取有关这些计划可能对目击和经历阿片类药物过量的高风险阿片类药物使用者的健康和结果产生影响的数据。我们有初步证据支持需要修改现有培训计划,以提高对阿片类药物过量的准确识别。此外,对文献的回顾表明,需要进行更广泛的研究,包括主动、长期的随访,以更好地确定与这种方法相关的所有好处和风险。具体来说,我们的调查将从纽约地区的多个地点招募正在戒毒的阿片类药物滥用者。所有参与者都将接受标准的阿片类药物过量教育培训,并在目睹他人服用过量或自己服用过量时随身携带纳洛酮。三分之一的参与者将被随机接受额外的深入心理社会教育,重点是识别和预防阿片类药物过量,以及纳洛酮的适当使用。另外三分之一的参与者将接受广泛的培训,并需要让配偶、伴侣、亲戚或朋友参与这项补充干预。我们期望这些社会心理干预措施(广泛的培训和对重要的其他人的培训)将改善药物过量的结果措施。我们还预计纳洛酮相关不良事件的发生率将降至最低,并且获得纳洛酮不会显着改变药物使用模式。这项研究的结果应该对美国这种新颖做法的风险和收益提供第一个前瞻性和系统性的评估,并教育该领域我们如何改进当前的做法。除了进行前瞻性研究外,我们还建议通过检查纽约市 DOHMH 收集的数据,对纳洛酮使用过量教育和培训的总体影响进行回顾性分析。具体来说,将比较具有提供过量预防培训设施的社区和不提供纳洛酮的设施的社区的致命和非致命阿片类药物过量率。我们预计,在提供阿片类药物过量预防培训和纳洛酮的社区,致命的阿片类药物过量发生率将显着降低。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANDRA D COMER其他文献
SANDRA D COMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANDRA D COMER', 18)}}的其他基金
Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose
经皮膈神经刺激治疗阿片类药物过量
- 批准号:
10681111 - 财政年份:2023
- 资助金额:
$ 54.05万 - 项目类别:
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials
开发逆转芬太尼及其类似物过量的单克隆抗体:从制造到临床试验
- 批准号:
10615519 - 财政年份:2022
- 资助金额:
$ 54.05万 - 项目类别:
Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal
舌下含服右美托咪定(一种 α2 肾上腺素能激动剂)用于治疗阿片类药物戒断的 1 期和 2 期研究
- 批准号:
10478324 - 财政年份:2022
- 资助金额:
$ 54.05万 - 项目类别:
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders
开发 ITI-333,一种 μ-阿片受体部分激动剂和 5HT2A 和 D1 受体拮抗剂,用于治疗阿片类药物使用障碍
- 批准号:
9841388 - 财政年份:2019
- 资助金额:
$ 54.05万 - 项目类别:
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components
多价阿片类疫苗成分的 1a/1b 期临床试验
- 批准号:
10782616 - 财政年份:2018
- 资助金额:
$ 54.05万 - 项目类别:
CERC-501 Kappa Antagonist for Nicotine Dependence
CERC-501 尼古丁依赖性 Kappa 拮抗剂
- 批准号:
9041849 - 财政年份:2016
- 资助金额:
$ 54.05万 - 项目类别:
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers
动态对比增强 MRI 测量药物滥用者的血脑屏障渗透性
- 批准号:
9066619 - 财政年份:2015
- 资助金额:
$ 54.05万 - 项目类别:
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers
动态对比增强 MRI 测量药物滥用者的血脑屏障渗透性
- 批准号:
8989439 - 财政年份:2015
- 资助金额:
$ 54.05万 - 项目类别:
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users
过量教育和向海洛因使用者开纳洛酮处方的风险和益处
- 批准号:
9330829 - 财政年份:2014
- 资助金额:
$ 54.05万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach
与阿片类药物使用障碍药物相关的口腔并发症的风险比较:混合方法
- 批准号:
10765049 - 财政年份:2023
- 资助金额:
$ 54.05万 - 项目类别:
Limbic Pallidum DBS for the treatment of severe alcohol use disorder
边缘苍白球 DBS 用于治疗严重酒精使用障碍
- 批准号:
10539383 - 财政年份:2022
- 资助金额:
$ 54.05万 - 项目类别:
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial
氯胺酮在急诊科治疗酒精使用障碍:一项双盲、安慰剂对照随机临床试验
- 批准号:
10593244 - 财政年份:2022
- 资助金额:
$ 54.05万 - 项目类别:
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial
氯胺酮在急诊科治疗酒精使用障碍:一项试点双盲、安慰剂对照随机临床试验
- 批准号:
10703512 - 财政年份:2022
- 资助金额:
$ 54.05万 - 项目类别:
A novel data-driven approach for personalizing smoking cessation pharmacotherapy
一种新的数据驱动的个性化戒烟药物治疗方法
- 批准号:
10578721 - 财政年份:2022
- 资助金额:
$ 54.05万 - 项目类别: